Treatment of Raynaud's Phenomenon in Limited Cutaneous Systemic Sclerosis

In patients with limited cutaneous systemic sclerosis (lcSSc), Raynaud's phenomenon (SSc-RP) is a common and clinically significant complication characterised by recurrent vasospastic attacks. Addressing SSc-RP is a key priority in the management of this condition.

Clinical scenario

This protocol is directed at Raynaud's phenomenon occurring in the setting of limited cutaneous systemic sclerosis — a population in which the frequency, duration, and severity of vasospastic episodes are primary treatment targets.

Treatment goals

Clinical success is defined by improvement in Raynaud's condition score, together with a meaningful reduction in both the daily frequency and the daily duration of Raynaud's phenomenon attacks.

Treatment approach (partial overview)

The protocol involves a class of agents known as PDE5 inhibitors. The full evidence-based regimen — including patient selection, sequencing, and clinical decision points — is available via the link below.

Instant Access to Structured Evidence-Based Regimens

References

Dihydropyridine-type calcium antagonists, usually oral nifedipine, should be used as first-line therapy for SSc-RP.

PDE5 inhibitors should also be considered for treatment of SSc-RP.

The PDE5 inhibitor group showed an overall improvement in Raynaud's condition score compared with placebo. Significant differences were also noted in daily frequency of RP attacks and daily duration of RP attacks in minutes.

DOI: 10.1136/ard-2024-226430

View source ↗